Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Update on Disclosed Matter]Status of US Subsidiary Satsuma Pharmaceutical’s Negotiation for Atzumi
SNBL Integrated Report 2025 part2
SNBL Integrated Report 2025 part1
SNBL ESG Data Book2025
Corporate Governance Report
Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP)
Notice Regarding Distribution ofInterim Dividends from Retained Earnings
Notice Regarding Differences between Consolidated Financial Forecasts and Actual Results for the Six Months Ended September 30, 2025
Presentation Materials for the First Six Months of the Fiscal Year Ending March 31, 2026
SHIN NIPPON BIOMEDICAL, First Half Ordinary Profit Decreases by 11%, Jul-Sep Ordinary Profit Decreases by 25%
SNBL’s Subsidiary, SNLD, Announces Posters to be Presented at the Upcoming International Congress of Parkinson’s Disease and Movement Disorders
Presentation materials on Financial Results for the First Three Months of the Fiscal Year ending March 31, 2026
Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2026 (Under Japanese GAAP)
SHIN NIPPON BIOMEDICAL, Apr-Jun (1Q) Ordinary Profit Increases by 51%
[Delayed] Corporate Governance Report
Notice Regarding Distribution of Year-end Dividends from Retained Earnings
(Corrections/Corrections of Numerical Data) Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)
Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)
SHIN NIPPON BIOMEDICAL, 8% Decrease in Ordinary Profit for The Current Fiscal Year
Presentation Materials for the Fiscal Year Ended March 31, 2025